NCT04982289View on ClinicalTrials.gov

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2024

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

ALXN1830

Administered as an SC infusion.

OTHER

Placebo

Administered as an SC infusion.

Trial Locations (1)

85028

Clinical Study Site, Phoenix

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY